These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 29146737

  • 21. An MRI study of immune checkpoint inhibitor-induced musculoskeletal manifestations myofasciitis is the prominent imaging finding.
    Daoussis D, Kraniotis P, Filippopoulou A, Argiriadi R, Theodoraki S, Makatsoris T, Koutras A, Kehagias I, Papachristou DJ, Solomou A, Kalofonos H, Liossis SN.
    Rheumatology (Oxford); 2020 May 01; 59(5):1041-1050. PubMed ID: 32344435
    [Abstract] [Full Text] [Related]

  • 22. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis.
    Verspohl SH, Holderried T, Behning C, Brossart P, Schäfer VS.
    Ther Adv Musculoskelet Dis; 2021 May 01; 13():1759720X211006963. PubMed ID: 33912248
    [Abstract] [Full Text] [Related]

  • 23. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
    Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O.
    Lancet Haematol; 2019 Jan 01; 6(1):e48-e57. PubMed ID: 30528137
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E, Mazzarella A, Antonazzo IC, Bendinelli N, Forcesi E, Tuccori M, Moretti U, Poluzzi E, De Ponti F.
    Target Oncol; 2019 Apr 01; 14(2):205-221. PubMed ID: 30927173
    [Abstract] [Full Text] [Related]

  • 29. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.
    Kostine M, Truchetet ME, Schaeverbeke T.
    Rheumatology (Oxford); 2019 Dec 01; 58(Suppl 7):vii68-vii74. PubMed ID: 31816082
    [Abstract] [Full Text] [Related]

  • 30. Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know?
    Gediz F, Kobak S.
    Curr Rheumatol Rev; 2019 Dec 01; 15(3):201-208. PubMed ID: 30659547
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Rheumatic Complications of Immune Checkpoint Inhibitors.
    Ghosh N, Bass AR.
    Med Clin North Am; 2021 Mar 01; 105(2):227-245. PubMed ID: 33589099
    [Abstract] [Full Text] [Related]

  • 34. Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors.
    de Malet A, Antoni G, Collins M, Soularue E, Marthey L, Vaysse T, Coutzac C, Chaput N, Mateus C, Robert C, Carbonnel F.
    Eur J Cancer; 2019 Jan 01; 106():106-114. PubMed ID: 30476730
    [Abstract] [Full Text] [Related]

  • 35. Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy.
    Bitton K, Michot JM, Barreau E, Lambotte O, Haigh O, Marabelle A, Voisin AL, Mateus C, Rémond AL, Couret C, Champiat S, Labetoulle M, Rousseau A.
    Am J Ophthalmol; 2019 Jun 01; 202():109-117. PubMed ID: 30772350
    [Abstract] [Full Text] [Related]

  • 36. Checkpoint inhibitors (CPI) and autoimmune chronic inflammatory diseases (ACIDs): tolerance and loss of tolerance in the occurrence of immuno-rheumatologic manifestations.
    Gremese E, Alivernini S, Ferraccioli ES, Ferraccioli G.
    Clin Immunol; 2020 May 01; 214():108395. PubMed ID: 32240819
    [Abstract] [Full Text] [Related]

  • 37. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
    Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud B, Scalbert C, Maanaoui S, Lesimple T, Martinez S, Marcq M, Chouaid C, Dubos C, Brunet-Possenti F, Stavris C, Chiche L, Beneton N, Mansard S, Guisier F, Doubre H, Skowron F, Aubin F, Zehou O, Roge C, Lambert M, Pham-Ledard A, Beylot-Barry M, Veillon R, Kramkimel N, Giacchero D, De Quatrebarbes J, Michel C, Auliac JB, Gonzales G, Decroisette C, Le Garff G, Carpiuc I, Vallerand H, Nowak E, Cornec D, Kostine M, Groupe de Cancérologie Cutanée, Groupe Français de Pneumo-Cancérologie, and Club Rhumatismes et Inflammations.
    Arthritis Rheumatol; 2019 Dec 01; 71(12):2100-2111. PubMed ID: 31379105
    [Abstract] [Full Text] [Related]

  • 38. Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature.
    Benfaremo D, Manfredi L, Luchetti MM, Gabrielli A.
    Curr Drug Saf; 2018 Dec 01; 13(3):150-164. PubMed ID: 29745339
    [Abstract] [Full Text] [Related]

  • 39. Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective.
    Steven NM, Fisher BA.
    Rheumatology (Oxford); 2019 Dec 01; 58(Suppl 7):vii29-vii39. PubMed ID: 31816079
    [Abstract] [Full Text] [Related]

  • 40. Rheumatic immune-related adverse events induced by immune checkpoint inhibitors.
    Zhong H, Zhou J, Xu D, Zeng X.
    Asia Pac J Clin Oncol; 2021 Jun 01; 17(3):178-185. PubMed ID: 32717098
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.